Amrinone
Amrinone is a pyridine phosphodiesterase 3 (PDE 3) inhibitor that is clinically used to treat congestive heart failure (CHF). Amrinone may be administered during cardiopulmonary bypass surgery. Amrinone exhibits positive inotropic activity, inducing vasodilation and increasing cardiac contractility through alterations in cAMP and Ca2+ signaling.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18838424
| Cas No. |
60719-84-8 |
|---|---|
| Purity |
≥98% |
| Formula |
C10H9N3O |
| Formula Wt. |
187.20 |
| Chemical Name |
5-Amino-(3,4-bipyridin)-6(1H)-one |
| IUPAC Name |
3-amino-5-pyridin-4-yl-1H-pyridin-2-one |
| Synonym |
Cartonic; Inocor; Vesistol; Wincoram |
| Melting Point |
294-297°C(dec.) |
| Solubility |
Insoluble in water. Slightly soluble in hot acetic acid and dimethylformamide. Soluble in dilute inorganic acids. |
| Appearance |
Yellow to light yellow crystalline Powder |
Coons JC, McGraw M, Murali S. Pharmacotherapy for acute heart failure syndromes. Am J Health Syst Pharm. 2011 Jan 1;68(1):21-35. PMID: 21164062.
van der Zypp A, Rechtman M, Majewski H. The role of cyclic nucleotides and calcium in the relaxation produced by amrinone in rat aorta. Gen Pharmacol. 2000 Apr;34(4):245-53. PMID: 11282218.
Hamada Y, Kawachi K, Yamamoto T, et al. Effects of single administration of a phosphodiesterase III inhibitor during cardiopulmonary bypass: comparison of milrinone and amrinone. Jpn Circ J. 1999 Aug;63(8):605-9. PMID: 10478810.
